Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications
Shots:
- Under the collaboration, CMS gains an exclusive license for developing & commercializing plus a non-exclusive license for manufacturing povorcitinib to treat non-segmental vitiligo, HS, PN, asthma & CSU across mainland China, Hong Kong, Macau, Taiwan & certain Southeast Asian regions
- Incyte will receive an up front payment, development & commercial milestones plus net-sales-based royalties for the product across these regions
- Povorcitinib (oral), a small molecule targeting JAK1, is currently under P-III assessment to treat non-segmental vitiligo and HS across regions excl. China and under P-II evaluation to treat PN, asthma & CSU
Ref: Incyte | Image: Incyte
Related News:- Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
